DE69733081D1 - Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen - Google Patents

Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Info

Publication number
DE69733081D1
DE69733081D1 DE69733081T DE69733081T DE69733081D1 DE 69733081 D1 DE69733081 D1 DE 69733081D1 DE 69733081 T DE69733081 T DE 69733081T DE 69733081 T DE69733081 T DE 69733081T DE 69733081 D1 DE69733081 D1 DE 69733081D1
Authority
DE
Germany
Prior art keywords
anticonvulsive
preparation
treatment
neuropathic pain
nmda receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733081T
Other languages
English (en)
Other versions
DE69733081T2 (de
Inventor
S Caruso
L Minn
W Lyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Inc
Original Assignee
Algos Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Pharmaceutical Corp filed Critical Algos Pharmaceutical Corp
Application granted granted Critical
Publication of DE69733081D1 publication Critical patent/DE69733081D1/de
Publication of DE69733081T2 publication Critical patent/DE69733081T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69733081T 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen Expired - Lifetime DE69733081T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2450896P 1996-08-23 1996-08-23
US24508P 1996-08-23
PCT/US1997/014680 WO1998007447A1 (en) 1996-08-23 1997-08-21 Anticonvulsant containing composition for treating neuropathic pain

Publications (2)

Publication Number Publication Date
DE69733081D1 true DE69733081D1 (de) 2005-05-25
DE69733081T2 DE69733081T2 (de) 2006-05-11

Family

ID=21820954

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733081T Expired - Lifetime DE69733081T2 (de) 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Country Status (9)

Country Link
US (2) US6187338B1 (de)
EP (1) EP0942752B1 (de)
JP (1) JP2001500121A (de)
AT (1) ATE293458T1 (de)
AU (1) AU4078897A (de)
CA (1) CA2264182A1 (de)
DE (1) DE69733081T2 (de)
ES (1) ES2241055T3 (de)
WO (1) WO1998007447A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500121A (ja) * 1996-08-23 2001-01-09 アルゴス ファーマシューティカル コーポレーション 神経障害性の痛みを治療する組成物を含む抗けいれん剤
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
KR100537707B1 (ko) * 1997-09-08 2005-12-20 워너-램버트 캄파니 엘엘씨 항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법
AU784225B2 (en) * 1997-09-08 2006-02-23 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU2002301365B2 (en) * 1997-09-08 2005-11-24 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1094817A1 (de) * 1998-07-09 2001-05-02 Warner-Lambert Company Zusammensetzungen enthaltend gaba-analoge und koffein
US6309858B1 (en) 1998-09-29 2001-10-30 Syntex (U.S.A.) Llc T-type calcium channel variants; compositions thereof; and uses
TR200103219T2 (tr) 1999-02-18 2002-04-22 Ortho-Mcneil Pharmaceutical, Inc. Nöropatik ağrının iyileştirilmesinde kullanım için aroil aminoasil piroller
AU3216600A (en) * 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
AU5824800A (en) * 1999-06-23 2001-01-31 Warner-Lambert Company Use of fosphenytoin for the treatment of acute neuropathic pain
ES2234651T3 (es) * 1999-08-20 2005-07-01 Ortho-Mcneil Pharmaceutical, Inc. Composicion que comprende una materia de tramadol y un farmaco anticonvulsivo.
AU2001271631A1 (en) 2000-06-30 2002-01-14 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
ES2632544T3 (es) 2001-06-07 2017-09-14 Analgesic Neuropharmaceuticals, Llc Tratamiento de dolor neuropático con el antagonista del receptor de N-metil-D-aspartato (NMDA) dextrometorfano
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
CN1642547A (zh) * 2002-01-16 2005-07-20 恩多制药公司 治疗中枢神经系统障碍的药物组合物和方法
MXPA04007896A (es) * 2002-02-13 2005-06-17 Beth Israel Hospital Metodos para tratar enfermedades vasculares.
JP2005518439A (ja) * 2002-02-26 2005-06-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
RS110504A (en) * 2002-06-21 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
PT1524981E (pt) * 2002-07-29 2009-06-17 Glaxo Group Ltd Formulações de libertação controlada contendo lamotrigina
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US7208477B2 (en) * 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
EP1638931A4 (de) * 2003-06-11 2007-11-07 Neuromolecular Inc Verfahren zum zielgerichteten einsatz eines therapeutischen mittels
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
EP1686967A4 (de) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
AU2005209310B2 (en) * 2004-01-29 2011-01-06 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions
EP1727538A2 (de) * 2004-02-13 2006-12-06 Neuromolecular Inc. Kombination aus einem nmda-rezeptor-antagonisten und einem antiepileptikum zur behandlung von epilepsie und anderen störungen des zns
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CA2578407A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
NZ553970A (en) * 2004-09-10 2010-01-29 Newron Pharm Spa Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2404750C2 (ru) 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
US8389578B2 (en) * 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
EP1874282B1 (de) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20060270742A1 (en) * 2005-05-02 2006-11-30 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
US20090143450A1 (en) * 2005-05-06 2009-06-04 University Of Maryland, Baltimore Method for treating central pain syndrom or for inducing centrally generated pain in an animal model
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
JP5050851B2 (ja) 2005-06-27 2012-10-17 小野薬品工業株式会社 疼痛治療剤
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US7855227B2 (en) 2005-12-22 2010-12-21 Newron Pharmaceuticals S.P.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
EP2428207A1 (de) * 2006-12-22 2012-03-14 Allergan, Inc. Alpha-2B Adrenerger Rezeptoragonist und Serotonin-Norepinephrin-Wiederaufnahmeinhibitor-Zusammensetzungen zur Behandlung von chronischen Schmerzen
CN103497114A (zh) 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
CA2701838A1 (en) * 2007-10-09 2009-04-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
CN102883601A (zh) 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
TWI816417B (zh) 2013-12-24 2023-09-21 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
MX2019006640A (es) 2016-12-06 2019-08-01 Topical Innovations Bv Fenitoina topica para el uso en el tratamiento del dolor neuropatico periferico.
WO2018106108A1 (en) 2016-12-06 2018-06-14 KEPPEL HESSELING, Jan Marius Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
CN112367990A (zh) * 2018-04-16 2021-02-12 生物基因麻省公司 治疗神经病理性疼痛的方法
WO2020054872A1 (ja) * 2018-09-14 2020-03-19 国立大学法人富山大学 急性帯状疱疹痛の治療剤
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
AU2021265602A1 (en) 2020-05-01 2023-01-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and ORF3 inhibitors as anti-covid-19 agents
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
EP0346445A4 (de) * 1987-12-22 1990-03-28 Ferkany John W Dextrophan-bekräftiger für antispasmenzubereitungen und verfahren.
US4906638A (en) * 1987-12-22 1990-03-06 Nova Pharmaceutical Corporation Dextromethorphan potentiator for anticonvulsant composition and method
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
JP2001500121A (ja) * 1996-08-23 2001-01-09 アルゴス ファーマシューティカル コーポレーション 神経障害性の痛みを治療する組成物を含む抗けいれん剤
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

Also Published As

Publication number Publication date
WO1998007447A1 (en) 1998-02-26
AU4078897A (en) 1998-03-06
EP0942752A1 (de) 1999-09-22
ATE293458T1 (de) 2005-05-15
DE69733081T2 (de) 2006-05-11
JP2001500121A (ja) 2001-01-09
US20010008889A1 (en) 2001-07-19
US6406716B2 (en) 2002-06-18
ES2241055T3 (es) 2005-10-16
CA2264182A1 (en) 1998-02-26
EP0942752B1 (de) 2005-04-20
US6187338B1 (en) 2001-02-13

Similar Documents

Publication Publication Date Title
DE69733081D1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
ATE214277T1 (de) Schmerzlindernde arzneistoffzusammensetzung
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
ATE288444T1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
BG103552A (en) Therapeutical forms
BR9508671A (pt) Método de alívio da dor e composição terapêutica
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
PL312198A1 (en) Application of procaine in obtaining a pharmaceutical preparation of analgesic activity with minimum motorial blocking effect
IL124730A (en) Compositions for the treatment of gastrointestinal disorders comprising a bismuth compound and one or more antimicrobials, and the use of bismuth and an antimicrobial compound for the preparation of such compositions
MX9804579A (es) Composiciones que contienen bismuto para la prevencion y tratamiento de trastornos gastrointestinales.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ENDO PHARMACEUTICALS INC. (N.D.GES.D. STAATES DELA

8364 No opposition during term of opposition